Business
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS”) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord i
About this update from Nurexone Biologic Inc
[{"type":"image","alt":"NurExone Biologic Inc","displaySize":"","headline":null,"caption":"NurExone Biologic Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/c6e879a2d8f96b03c7effe65222bd22d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LdPJTZr5I78IC83xVN.ElQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4/https://media.zenfs.com/en/globenewswire.com/c6e879a2d8f96b03c7effe65222bd22d","width":300,"height":70}},"lazy":false},{"type":"text","content":"TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS”) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord injury and optic nerve damage, with additional potential indications including traumatic brain injury and facial nerve injury.","length":645,"tagName":"p"},{"type":"text","content":"The Company’s audited consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 and accompanying management discussion and analysis can be accessed by visiting the Company's website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.","length":284,"tagName":"p"},{"type":"text","content":"2025 Highlights and Significant Milestones","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Advancement of ExoPTEN Therapy: Throughout 2025, the Company continued to refine its preclinical data and address feedback from the U.S. Food and Drug Administration (“FDA”) as it advanced key milestones towards the submission of an Investigational New Drug (“IND”) application for ExoPTEN. NurExone generated additional encouraging preclinical results that strengthened confidence in ExoPTEN’s therapeutic potential, while also advancing work on dosing, manufacturing, and product characterization. These efforts support preparation for regulatory review, clinical development and first-in-human clinical trials.","length":618,"tagName":"p"}]},{"val":[{"type":"text","conten...